Asia Fresh News

Asia Fresh Stories

Archive for December 3rd, 2013

National Instruments’ Graphical System Design Summit 2013 in Southeast Asia comes to Vietnam

leave a comment »

HO CHI MINH CITY, Vietnam, Dec. 3, 2013 /PRNewswire/ — National Instruments’ annual premier conference, Graphical System Design (GSD) Summit 2013, opens in Ho Chi Minh City today, before its final stop in Hanoi on December 10. Held across 11 cities in Southeast Asia, the GSD Summit brings latest technologies in control, design, test and measurement and automation to engineers, scientists, educators, researchers and NI’s partners. It also showcases how the graphical system design approach can help in accelerating innovation, discovery and productivity.
Chandran Nair, Managing Director for National Instruments in Southeast Asia, says, “An integrated approach with flexible tools will help engineers and scientists optimize their performance and cost. National Instruments has long-standing relationships with partners and customers from different industries in Vietnam, and we hope to continue supporting them with leading-edge tools and technologies to help them focus on their expertise and contribute to the economic development of the country.”
With a large population, rapid economic development and rising foreign investment supporting manufacturing and exports, Vietnam is an important market for National Instruments. Since the opening of its office in Ho Chi Minh City in 2011, NI has seen strong growth in industries such as automotive, infrastructure, oil and gas, manufacturing, as well as in the research and academic sectors.
“Vietnam has been showing high GDP growth in 2013, with significant contribution from the manufacturing and export sectors,” says Chandran. “The government has set a target for Vietnam electronics exports to reach US$40 billion by 2017, and we are committed to support this goal by helping strengthen the local engineering ecosystem.”
GSD Summit 2013 features full day interactive technical sessions, presentations and demonstration to highlight innovative uses of the graphical system design platform; besides hands-on workshops and exhibitions to showcase NI’s cutting-edge products and technologies serving a wide range of sectors from engineering (NI LabVIEW 2013) to academia (NI MyDAQ and NI Elvis).
For more information, please visit: http://vietnam.ni.com/gsdsummits/2013-hcm
About National Instruments
Since 1976, National Instruments (http://www.ni.com) has equipped engineers and scientists with tools that accelerate productivity, innovation and discovery. NI’s graphical system design approach to engineering provides an integrated software and hardware platform that speeds the development of any system needing measurement and control. The company’s long-term vision and focus on improving society through its technology supports the success of its customers, employees, suppliers and shareholders.
National Instruments, NI, ni.com, LabVIEW and NI Elvis are trademarks of National Instruments. Other product and company names listed are trademarks or trade names of their respective companies.
Editor Contact: Jessie Lee, National Instruments (Email: jessie.lee@ni.com; Phone: +65-6226-5886)
Source: National Instruments

Written by asiafreshnews

December 3, 2013 at 5:46 pm

Developing Quality in the Asian Pharmaceutical Industry Begins with QbD

leave a comment »

KUALA LUMPUR, Dec. 2, 2013 /PRNewswire/ — As Asia emerges as a major engine of global economic growth, the pharmaceutical and biotechnology industries in the region are expected to experience intensified competition. According to the Economist Intelligence Unit (EIU), regional pharmaceutical sales are expected to hit USD386bn, reflecting an annual average growth rate of more than 13%.

Therefore, competition is likely to remain intense. The incorporation of Quality by Design (QbD) in the manufacturing process will help propel regional manufacturers to achieve quality and cost effectiveness to successfully compete in this growing market. Mr. Valentino Dhiyu, Formulator, Invida notes, “Product and process development account for 15-30% of overall R&D expenditure. Based on the experience of some companies, organisations that embrace QbD can significantly reduce costs, improve products, shorten time to launch, reduce risk, and improve patient benefits.”

CPhI — Quality by Design is a three-day technical event from 24-26 February 2014 in Kuala Lumpur, Malaysia that includes an exclusive two-day workshop, “Quality by Design Implementation Roadmap Masterclass”. The event will address business drivers, regulatory frameworks, risks, principles and approach for QbD by speakers from both regulators and manufacturers such as the Food and Drug Administration – Philippines, Biocon and Invida.

Mr. Nitin Madhukar Kadam, Assistant Manager R&D (Formulation), Medica Pharmaceutical Industries commented, “Asia has a huge landscape to grow and implement the QbD concept because the new era of approaches to quality has just began to harmonise global quality pharmaceuticals.” CPhI — Quality by Design is an opportunity for those in the pharmaceutical research and development, formulation, analytical, regulatory affairs and quality areas to explore and integrate QbD to in their organisations and building quality into product development.

For more information about CPhI — Quality by Design, please visit: http://www.qualitybydesign-asia.com

Media Contact:

Marcus Chan
Senior Marketing Associate (ASEAN)
DID: +603-2176-8703
HP: +6012-227-7286
E-mail: Marcus.chan@ubm.com

About CPhI:

CPhI Conferences deliver the latest pharma market insight, in-depth case studies and exceptional networking opportunities through a programme of high-level conferences. The worldwide series of events, spanning four continents, provides the optimum forum for you to learn, make new business connections and identify the latest growth opportunities.

Delivered by expert teams in each region, every conference is extensively researched with leading professionals, ensuring that CPhI Conferences tackle the most business critical issues facing the pharma industry today.

For more information about CPhI, please visit – http://www.cphiconferences.com

About the Organiser

UBM is a global live media and B2B communications, marketing service and data provider. We help organisations make connections, communicate their proposition and do business effectively. We enable professional people in more than 40 countries around the world to connect and engage with each other, with the markets they serve and with the information they need to succeed. And we do this by whatever means works best — at live events, through digital media or in publications.

Our 6,500 expert staff are deeply embedded in the many specialist communities we serve, bringing both an unusual depth of understanding and real know-how. We organise hundreds of live events each year; we provide data, marketing and information products; we offer a portfolio of market-leading online and print titles; and we support professional communicators through our targeting, distribution and monitoring services.

Our culture of innovation and collaboration brings our people together around common interests to create value, enhancing our ability to do exactly the same for UBM customers. So, whatever their business and wherever they operate, our customers do better business through us.

For more information about UBM, please visit – http://www.ubm.com
Source: UBM Conferences (ASEAN)

Written by asiafreshnews

December 3, 2013 at 4:23 pm

Posted in Uncategorized

Unmanned Ground Systems: Semi-Autonomy is the Way Forward over the Next Ten Years, says Frost & Sullivan

leave a comment »

Military vehicle manufactures may be reluctant to invest heavily in unmanned systems research and development due to a largely undefined need

LONDON, Dec. 2, 2013 /PRNewswire/ — Unmanned Ground Vehicles (UGV) represent a tiny proportion of vehicle inventories globally but replacing and complementing manned vehicles with unmanned systems is a powerful opportunity. As yet, it has not been defined how the technology will be best utilised or how new systems will be integrated into force structures. According to Frost & Sullivan in the five-to-ten-year timeframe there will be only a limited proliferation of unmanned technology into the market.

“Currently, the US is at the forefront in terms of integration and acquisition of unmanned systems into its military land vehicle fleet,” said Programme Manager, Aerospace, Defence & Security, Richard Hilton. “But even the US has dramatically scaled back its intent to integrate unmanned systems in line with wider cut backs and defence sequestration. Moreover, there are no really significant procurement programmes for UGVs in any other region.”

The commercial automotive industry is leading the way in unmanned vehicle systems. Commercial vehicle manufacturers with a significant defence-industry footprint may be able to migrate technology into military vehicles once costs are driven down through increasingly accessible commercial supply. Developments in the commercial sector could provide the tipping point for mass integration of some form of unmanned systems technology in less than ten years with the majority of vehicle fleets, particularly in the application of logistics, having an optional unmanned capability or semi-autonomy, adapting technology from commercial innovations to improve vehicle safety.

“It is interesting to see the parallels between the developments in the unmanned vehicle segment in which lessons could be learned for the wider military vehicles market,” added Hilton. “Technology integration through Commercial off- the-shelf (COTS) may become key in all segments and is of growing interest to end users seeking to de-risk technology integration.”  If these systems are proven commercially, easily trained on, and easily maintained, it becomes much easier to assimilate them into operational structures and concepts.

To date, military vehicle manufactures seem reluctant to invest heavily in unmanned systems research and development whilst end users are focused on a more-limited set of procurement objectives in the present-day fiscal climate. The real opportunity in the application of unmanned systems may well lie in the ability to assimilate effective C4ISR systems to maximise the low-cost platform availability and exploit 24-hr persistence as seen in the air domain.

“For now, in the upcoming five to ten years, there will be only a limited growth of unmanned technology into the market. Perhaps, in five years, semi-autonomous applique add-ons to vehicles will begin the transformative process thanks to commercial advancements, providing the much-needed catalyst to trigger greater exploitation of promising potential,” summarised Hilton.

If you would like to learn more about Frost & Sullivan’s Market Insight on Unmanned Ground Vehicles, please contact Joanna Lewandowska, Corporate Communications, at joanna.lewandowska@frost.com. Please include your full contact details in the query.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Contact:
Joanna Lewandowska
Corporate Communications – Europe
P: +48 22 481 62 20
E: joanna.lewandowska@frost.com
http://www.frost.com
www.twitter.com/frost_sullivan
Join our ADS Forum on LinkedIn

Source: Frost & Sullivan

Written by asiafreshnews

December 3, 2013 at 4:10 pm

Posted in Uncategorized

New Breast Cancer Study Results Published in The Lancet Compare Targeted Radiotherapy During Surgery With ZEISS INTRABEAM to Traditional Post-Surgical Radiotherapy Treatment

leave a comment »

JENA, Germany, Dec. 2, 2013 /PRNewswire/ —

5-year results of international TARGIT-A clinical trial support targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM as non-inferior to external beam radiotherapy (EBRT) for selected early stage breast cancer patients.

Results of the TARGIT-A clinical trial published in The Lancet

A new clinical trial for breast cancer, published in The Lancet, one of the world’s leading medical journal, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients.

“The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment at the time of her operation, with lower toxicity to the breast, the heart and other organs. Our research supports the use of TARGIT concurrent with lumpectomy, provided patients are selected carefully, and should allow patients and their clinicians to make a more informed choice about individualizing their treatment, saving time, money, breasts, and lives,” according to Professor Jayant S. Vaidya, FRCS MD, PhD from the international TARGIT investigators group, in the accompanying press release on the Lancet publication of the research study.

Since 1998, the international TARGIT research group has investigated whether radiotherapy targeted to the tumour bed at the time of surgery can reduce the risk of recurrence in early breast cancer as effectively as the traditional three to six week EBRT.

Traditionally, whole-breast EBRT is given after lumpectomy (breast conserving surgery) to reduce the risk of recurrence of cancer in the breast and of breast cancer mortality. EBRT typically is given over a course of three to six weeks requiring patients to receive treatment at radiotherapy centers for 20-30 days. In some cases, women suitable for breast conserving surgery, but living far from a radiotherapy center and unable to attend daily post-surgical treatments may even undergo mastectomy as an alternate.

In the TARGIT approach, during surgery after removal of the tumor, the affected tissue in the tumor bed is irradiated from within the breast using the ZEISS INTRABEAM. The TARGIT study results show that targeted intraoperative radiotherapy delivered with ZEISS INTRABEAM can reduce the risk of recurrence of the cancer as effectively as a traditional 3- to 6-week course of whole breast irradiation in selected women with invasive ductal carcinoma.

The TARGIT-A trial has been to date the largest multicenter randomized clinical trial for intraoperative radiotherapy (IORT) in the field of partial breast irradiation, with 3451 patients in 33 international centers from Europe, the United States, and Australia. The TARGIT-A trial followed an individualized risk-adapted approach, meaning, that patients who had received TARGIT at the time of surgery showed in the final pathology additional unforeseen risk factors, received supplemental EBRT, which occurred for about 15% of the patients. The 5-year results for local recurrence and the first analysis of overall survival of the TARGIT-A trial have now been reported.

Comparing TARGIT with EBRT the difference in 5-year local recurrence between the two treatments was less than 2.5% and therefore considered “non-inferior” to standard EBRT (daily doses for 3-6 weeks) in treating the cancer. Overall mortality was 3.9% with TARGIT and 5.3% with EBRT, due to fewer deaths from cardiovascular causes and other cancers.

Based on statistical comparison of breast cancer recurrence, number of deaths and side effects of TARGIT versus EBRT the authors conclude: “TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol.”

“We commend the international TARGIT group pioneered by Professor Jayant Vaidya and Professor Michael Baum for this outstanding research on this new treatment option that can benefit many breast cancer patients. The TARGIT group’s research will further enhance adoption by radiation oncologists and breast surgeons worldwide and will broaden the application of our ZEISS INTRABEAM for this new option in the fight against cancer,” says Dr. Ludwin Monz President and CEO of Carl Zeiss Meditec AG.

The Lancet publication of the results of the TARGIT-A study can be found at http://press.thelancet.com/TARGIT.pdf

http://www.meditec.zeiss.de/presse

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It is a provider of total solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2011/12 (ended 30 September) the 2,400 employees of the company generated revenue totaling EUR 862 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the company’s presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65% are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress for more than 160 years and enhances the quality of life of many people around the globe.

Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information, please go to: http://www.meditec.zeiss.com/

Contact for the press:

Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone +49(0)3641-220-331, Email: press.meditec@zeiss.com

Alice Swinton, Group Communications, Carl Zeiss Meditec, Inc.
Phone +1-925-557-4317, Email: alice.swinton@zeiss.com

For investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49(0)3641-220-116, Email: investors.meditec@zeiss.com

Source: Carl Zeiss Meditec AG

Written by asiafreshnews

December 3, 2013 at 3:07 pm

Posted in All releases

Frost & Sullivan: Impact of Big Data on the Automotive Industry – Explicit Savings of About $800 per Vehicle per Year

leave a comment »

Web conference on Big Data in Automotive helps address rising warranty costs and enables data sharing networks in the industry

LONDON, Dec. 2, 2013 /PRNewswire/ — Big data is not a new phenomenon in the automotive industry. The increasing presence of connectivity, with short-to mid-terms promising high-speed/high-bandwidth connectivity like LTE (long term evolution) in the car, is one of the key reasons for pursing big data in the industry. The shift is taking place due to the need to cut down on spiralling warranty costs and to create a data sharing network between the dealer, customer, OEM and others.

Frost & Sullivan is organising a web conference, entitled Impact of Big Data on the Automotive Industry, which is taking place on Tuesday, 10 December 2013, at 3.00 p.m. GMT. Frost & Sullivan Program Manager, Niranjan Manohar, and Global Practice Director Automotive & Transportation, Sarwant Singh, will discuss emerging trends and opportunities for the Big Data Automotive Industry.

To participate in this complimentary web conference, please email Katja Feick at katja.feick@frost.com with your full contact details. Upon receipt of the above information, a registration link will be e-mailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

Participants of this web conference will learn about key big data features and services, understand societal, technological and other related challenges, as well as identify ways to evolve under the existing value chain.

“There is an increasing need to cut down spiralling warranty costs, especially the ones caused due to software failure, which was the reason for 60 percent of the recalls,” says Mr. Manohar. “Original equipment manufacturers (OEMs) need data related to the vehicle’s age, performance, and failure scenarios to reduce warranty spend.”

Frost & Sullivan expects 60 percent of the North American OEMs to come up with their big data strategy and offerings in the next two years enabled by the move to high bandwidth embedded connectivity technologies like LTE. OEMs develop different approaches to reach their targets; the killer OEMs will be those that can use predictive data analytics to impact a 1-3 percent reduction in warranty costs along with other important software and firmware over-the-air-updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:    Start the discussion

Join Us:           Join our community

Subscribe:      Newsletter on “the next big thing”

Register:        Gain access to visionary innovation

Contact:

Katja Feick
Corporate Communications – Europe
P: +49 (0) 69 7703343
E: katja.feick@frost.com
http://www.frost.com
www.twitter.com/FS_Automotive
Join our Forum on LinkedIn: Future of Mobility

Source: Frost & Sullivan

Written by asiafreshnews

December 3, 2013 at 2:25 pm

Posted in Uncategorized

Aptuit Names Jonathan Goldman As CEO

leave a comment »

GREENWICH, Conn., Dec. 2, 2013 /PRNewswire/ — Timothy C. Tyson, Chairman of Aptuit LLC, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO), completing the company’s senior management leadership team. (Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO) Dr. Goldman will focus his efforts on the growth of Aptuit as a leading provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company after achieving significant success at ICON Clinical Research, a leading global Contract Research Organization that specializes in the provision of clinical and other solutions that support Phase I-IV clinical studies. Dr. Goldman stated, “I’m delighted to join Aptuit, and look forward to working closely with the entire team to leverage an outstanding value proposition that is unique in our industry. Pharma has an unmet need for lower cost, increased speed and better quality in drug discovery and development. Aptuit is the ideal partner to meet these needs across a comprehensive suite of services, supported by an approach that is both scientific and innovative. I look forward to continued growth of the company as the partner of choice for drug developers.” At ICON, Dr. Goldman was most recently Executive Vice President, Global Strategic and Business Development and a member of the senior leadership team. His accomplishments included record growth levels of sales, and the development of transformative business relationships with leading pharmaceutical and biotechnology companies. Previously, his roles at ICON included Executive Vice President, Operations, Strategic Programs and Chief Medical Officer, ICON Medical Imaging. Before joining ICON, Dr. Goldman served for 7 years as the Chief Medical Officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held honorary academic positions of increasing responsibility at the University of California since 2000, most recently as Associate Clinical Professor of Medicine in the Division of Cardiology. He holds a medical degree from St. Bartholomew’s Hospital Medical College, University of London, and MBA degrees from Columbia University in New York, and the University of California, Berkeley. Mr. Tyson commented, “We’re enthusiastic that Jonathan is joining us. He brings exceptional experience in science, sales and medicine, along with the innate talents that are needed to advance us to the next level of growth and accomplishments. His collaborative approach to understanding and satisfying the unmet needs of our clients makes him the perfect complement to our senior management team.” Stuart Needleman, Aptuit’s President and Chief Operating Officer, added, “Over the past few years, we have achieved an impressive track record of success in delivering drug discovery and development results in multiple therapeutic areas. I am especially proud of recent results we have delivered, since they enabled our clients to succeed despite some very difficult circumstances. Aptuit continues to forge ahead on a serious path of aggressive growth, and Jonathan is an industry leader who can help us to get to the next level through his focus on top line opportunities.” For more information, please send an email to info@aptuit.com or contact Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com. Aptuit LLC provides the most complete set of integrated early to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, and Pharmaceutical Sciences. The company maintains five global facilities with approximately 800 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Aptuit, visit http://www.aptuit.com Source: Aptuit

Written by asiafreshnews

December 3, 2013 at 12:28 pm

Posted in Uncategorized

Digicel Group and YSH Finance Sign Agreement with Ooredoo Myanmar

leave a comment »

KINGSTON, Jamaica, Dec. 2, 2013 /PRNewswire/ — Digicel Group and YSH Finance Ltd (comprising Yoma Strategic Holdings Ltd (“Yoma Strategic”) and First Myanmar Investment Co., Ltd (“FMI”) today announced that their reorganised consortium, Digicel Asian Holdings, has signed an agreement with Ooredoo Myanmar to develop, construct and lease telecommunications towers in the Republic of the Union of Myanmar as part of Ooredoo’s commitment to deploy a world-class telecommunications network across the country.

Digicel Asian Holdings’ company in Myanmar, Myanmar Tower Company, will be amongst the first telecommunications tower companies to begin construction in the Republic of the Union of Myanmar and, through its multi-tenancy towers, will help all telecommunications operating companies achieve their aims of rapidly deploying telecommunications coverage across the country.

Commenting on the announcement, Mr. Denis O’Brien, Chairman of Digicel Group, said; “We are delighted to work with Ooredoo to help develop a high quality telecommunications network across the Republic of the Union of Myanmar, contribute to the growth of the Myanmar economy and benefit Myanmar citizens across all of the country’s States, Regions and Union territories.”

Mr. Serge Pun, Chairman of Yoma Strategic and FMI, added; “Today’s announcement is a significant step in the economic and social development of the Republic of the Union of Myanmar. We are delighted to play our part in such development and look forward to working closely with the Government, authorities, telecommunications operators and other local companies.”

About Digicel

Digicel Group Limited is a leading global telecommunications provider with operations in 31 markets in the Caribbean, Central America and Asia Pacific. After 12 years of operation, total investment to date stands at over US$4.5 billion worldwide. The company is renowned for delivering best value, best service and best network.

Digicel runs a host of community-based initiatives across its markets and has set up Digicel Foundations in Jamaica, Haiti, Papua New Guinea and Trinidad and Tobago which focus on educational, cultural and social development programmes.

Digicel is the lead sponsor of Caribbean, Central American and Pacific sports teams and individuals including the world’s fastest man, Usain Bolt and Special Olympics teams throughout these regions. Digicel also sponsors the West Indies cricket team.

Visit www.digicelgroup.com for more information.

About YSH Finance Limited

YSH Finance Ltd is part of the SPA Myanmar Group, one of the leading business groups in Myanmar, with companies active in key business sectors, including financial services, real estate development, automobile distribution, agriculture, manufacturing, services, retail and travel and tourism.

YSH Finance Ltd is owned by First Myanmar Investment Co., Ltd (“FMI”) and Yoma Strategic Holdings Ltd (“Yoma Strategic”), two public companies within the SPA Myanmar Group.

In 1992, Mr. Pun set up FMI, a public company in Myanmar with over 4,500 shareholders, all of whom are Myanmar nationals. Employing approximately 5,000 people within the Group, FMI is active in a broad range of activities in Myanmar.

In 2006, Mr. Pun led Yoma Strategic to a successful listing on the mainboard of the Singapore Stock Exchange, which is today an internationally publicly listed company offering investors direct exposure to Myanmar.

Source: Digicel Group

Written by asiafreshnews

December 3, 2013 at 10:42 am

Posted in All releases